Endovascular Treatment of Epistaxis

P.W.A. Willems, R.I. Farb and R. Agid

*AJNR Am J Neuroradiol* 2009, 30 (9) 1637-1645
doi: https://doi.org/10.3174/ajnr.A1607
http://www.ajnr.org/content/30/9/1637

This information is current as of September 26, 2023.
Epistaxis is a common medical condition, with approximately 60% of the adult population having experienced at least 1 episode during their lives. Fortunately, most cases resolve spontaneously, and only 6% of epistaxis cases require medical attention, accounting for 0.46% of all emergency department visits in the Unites States. Large series have shown epistaxis to be equally frequent in males and females. The age distribution exhibits a mild peak before 20 years of age and a more prominent age-related increase after 40 years of age. The latter increase may reflect the increase of vascular disease, hypertension, iatrogenic and pathologic bleeding, and falls as a cause of trauma. Seasonal variation has also been well documented, with an incidence increase during winter months. This may reflect the influence of humidity, temperature, and the greater prevalence of upper respiratory infections.

Most cases of epistaxis arise from the anterior septal area, also known as the Little area. This area is vascularized by the Kiesselbach plexus, which is supplied by branches of the external carotid artery (ECA), including the sphenopalatine artery (SPA), descending palatine artery (DPA), and superior labial artery (SLA), as well as the anterior and posterior ethmoidal arteries (AEA and PEA), which branch off the ophthalmic artery (OphA).6 Because this area is readily accessible, hemorrhage from this region can usually be managed by applying pressure to the nostrils, chemical or electrocautery, topical hemostatic or vasoconstricting agents, cryotherapy, hot water irrigation, or anterior nasal packing together with the management of underlying risk factors such as hypertension and oral anticoagulation.

In only approximately 5% of cases, the origin of the epistaxis lies more posteriorly on the nasal cavity, causing these initial measures to fail. In most cases, an attempt will be made to control such posterior bleeding with the application of anterior and posterior packs (AP packs). These packs should be applied with care and under patient monitoring because they can lead to nasal trauma, vaginal response, aspiration, infection, and airway obstruction, leading to hypoxia, myocardial infarction, and even death. Their success rate has been reported to lie between 48% and 83%. In the remaining patients, bleeding either continues despite packing or recurs after removal of the AP packs. Subsequent treatment can consist of either surgical ligation or endovascular embolization of the arteries supplying the posterior nasal fossa. Historically, the definitive treatment for intractable posterior epistaxis consisted of transantral surgical ligation of branches of the internal maxillary artery (IMA), with or without ligation of the AEA. More recently, endoscopic surgical procedures have been described for direct cauterization of the active bleeding site or ligation of the SPA. Endovascular treatment of epistaxis was first presented as an alternative to surgery by Sokoloff et al in 1974 and consisted of particle embolization of the ipsilateral IMA. The technique was later refined by Lasjaunias et al, stressing the need for a standardized angiographic and therapeutic approach. It has gained increased acceptance, and several large series have been reported.

Preembolization Angiography and Vascular Anatomy
Lasjaunias et al stressed the importance of obtaining a diagnostic preembolization angiogram of the internal carotid artery (ICA) and ECA. In a minority of cases, this may reveal specific abnormalities indicating the cause and location of the hemorrhage. These include contrast extravasation, a tumor blush, a vascular malformation, a traumatic pseudoaneurysm, or another unusual ICA source of epistaxis. Furthermore, angiography enables identification of vascular anomalies, variants, or anastomoses between the ECA and ICA or OphA that could increase the risk of complications, such as stroke or blindness during embolization. These findings may influence the embolization protocol or even lead to aborting the procedure and referral to surgery.

The normal sinonasal vascular anatomy is presented in Fig 1. The terminal branch of the IMA, the SPA, provides the dominant supply to the nasal cavity. The roof of the nasal cavity is supplied by the AEA and PEA, which branch off the OphA. The floor of the nasal cavity is supplied by the ascending palatine artery (APA) and DPA, branches of the facial artery (FA) and IMA respectively. Finally, minor supply is provided anteriorly by the SLA, a branch of the FA, and posteriorly by branches from the ascending pharyngeal artery (APhA).

Even in the absence of vascular anomalies or clearly visible anastomoses, a number of small vessels still serve as potential connections between the ECA and ICA. These include the ar-
tery of the foramen rotundum, the vidian artery, the middle meningeal artery (MMA), the accessory meningeal artery, the APHa, the inferolateral trunk (ILT), the meningohypophysial trunk, and communications between the FA, SPA, and OphA.21,22 These “dangerous” anastomoses may open in case of increased pressure during embolization. Inadvertent embolization of the ICA or OphA through these anastomoses may lead to stroke or unilateral blindness, respectively. Furthermore, embolization of the OphA can also occur if it is supplied by the ECA instead of the ICA, either due to an anatomic variation or due to collateralization in the face of ICA stenosis.

**Embolization in Idiopathic Posterior Epistaxis**

The distribution of causes of epistaxis differs per center, depending on the type of population it serves and the referral patterns. Generally, at least 70% of cases are idiopathic.19,20 In most of these cases, findings of angiography will be normal. This normal initial angiographic finding likely relates to the AP packs, which are invariably in place, tamponading the bleeding site. In these cases, a routine embolization protocol is used, with the goal of diminishing flow to the bleeding mucosa but allowing sufficient collateral flow to avoid necrosis. Because embolization through the ICA, OphA, and APHa cannot be considered safe, the single most important vessel to embolize is the ipsilateral IMA and its branches. Due to the anastomoses between ICA and ECA described above, embolization should only be performed with a stable microcatheter position sufficiently distal to the origins of the accessory meningeal artery and the MMA. Placing the microcatheter distal to the middle deep temporal artery (MDTA) as well may avoid

<table>
<thead>
<tr>
<th>Step</th>
<th>Action</th>
<th>Clarification</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Angiogram of il* ICA</td>
<td>Verify supply to the OphA and choroidal blush from the ICA; rule out an ICA source of bleeding; check for extensive supply to nasal mucosa from the EAs</td>
</tr>
<tr>
<td>2</td>
<td>Angiogram of il ECA</td>
<td>Rule out vascular anomalies; check for dangerous anastomoses between ECA and ICA; rule out nonidiopathic causes of epistaxis</td>
</tr>
<tr>
<td>3</td>
<td>Embolization of il IMA</td>
<td>Selective catheterization of IMA, distal to MDTA, and embolization with suspension of PVA particles (250–350 μm) in contrast medium; sometimes followed by 1 or 2 Gelfoam pledgets</td>
</tr>
<tr>
<td>4</td>
<td>Embolization of il FA</td>
<td>Performed if significant supply to nasal mucosa from FA; selective catheterization of FA, distal to SMA, and embolization with suspension of PVA particles (250–350 μm) in contrast medium</td>
</tr>
<tr>
<td>5</td>
<td>Repeat 1–4 on cl* side</td>
<td>Due to collaterals between il and cl vasculature, we routinely include the cl side in our protocol</td>
</tr>
<tr>
<td>6</td>
<td>Transfer to ENT department</td>
<td>The packs are usually removed the following day by the ENT department</td>
</tr>
</tbody>
</table>

**Note:**—il indicates ipsilateral; cl, contralateral; ENT, ear-nose-throat; EAs: ethmoidal arteries (anterior and posterior); ICA, internal carotid artery; OphA, ophthalmic artery; ECA, external carotid artery; IMA, internal maxillary artery; MDTA, middle deep temporal artery; PVA, polyvinyl alcohol; FA, facial artery; SMA, submandibular artery. * il and cl indicate the side of bleeding or, if the patient bleeds from both nostrils, the side where bleeding started.
postembolization pain and trismus. A suspension of embolic and contrast material is subsequently injected under fluoroscopic control, until significant flow reduction is noted in the IMA branches. Injection of embolic material should not be overly powerful, to avoid reflux of embolic material into dangerous anastomoses. A wedged catheter position should also be avoided because this will allow buildup of injection pressure opening up dangerous anastomoses.

When the embolization is performed in a flow-guided fashion, embolization of the OphA may still occur if it is supplied by the ECA instead of the ICA. Therefore, one should confirm choroidal blush from the ICA, before embolization. Additional embolization of the ipsilateral FA has been reported to increase the success rate. Some authors will also embolize the contralateral IMA and even the contralateral FA, especially when these show substantial collateral supply. The Table outlines the protocol used at our institution for embolization of intractable idiopathic posterior epistaxis.

Performing the embolization with the benefit of general anesthesia is usually preferable for both the patient and interventionalist. To perform this procedure swiftly, safely, and effectively, we require the patient to lie quietly in the supine position. This is best accomplished with intubation and control of the airway should bleeding occur during the procedure, despite the packs. Materials frequently used for embolization include pledgets of gelatin sponge (Gelfoam; Pfizer, New York, NY); Gelfoam powder (Pfizer); polyvinyl alcohol (PVA) particles, ranging in size from 50 to 700 μm; platinum coils; or a combination of materials. Swine experiments have shown that different-sized materials cause the same sharp drop in nasal blood flow to a still viable level. Blood flow returned to baseline in 2–8 days, depending on the size of the material used, with smaller particles causing a longer effect. Midsized embolic material may balance the duration of therapeutic effect against the risk of ischemia, which could result in necrosis or cranial nerve palsy. Smaller particles (50–150 μm) are also discouraged because they are more likely to enter dangerous anastomoses. Thus, most recent reports mention the use of PVA particles, usually between 150 and 500 μm, with or without the subsequent addition of Gelfoam sponge pledgets or platinum coils.

The literature is inconsistent with regard to the timing of AP pack removal. Some authors do not remove the packs immediately, presumably expecting the combination of treatments to increase the overall success rate. Others remove the packs in the angiography suite, allowing them to perform additional embolization if bleeding has not yet ceased.

**Other Causes of Intractable Epistaxis**

In a minority of cases, a clear cause for the epistaxis will be known or found during angiography. Because the causes may
alter the treatment protocol, it is important to take note of them. We will discuss a number of different reported etiologies of epistaxis and their implications for the endovascular treatment strategy.

**Traumatic Epistaxis**

Although life-threatening hemorrhage associated with maxillofacial trauma is considered rare, massive exsanguinating epistaxis can occur due to laceration of ECA branches. This can be addressed after securing the airway, which may be compromised by bleeding into the oral cavity, mandibular fractures, soft-tissue swelling, and obtundation from traumatic brain injury. Failure to control blood loss with less invasive measures, including manual pressure, nasal packing, suture closure, and surgical ligation of obvious bleeding sites, will prompt either surgical exploration or transarterial embolization. If massive bleeding with severe shock is still present at this time, immediate sacrifice of the ECA may be the safest option. When time permits, however, patient history, CT examination, and contrast extravasation during angiography can indicate the site of bleeding, allowing selective catheterization and embolization as distal as possible to spare normal arterial territories.

When arterial damage leads to pseudoaneurysm formation, patients can present with epistaxis in a delayed fashion. Aside from arising from arteries vascularizing the oronasal cavity (Fig 2), such traumatic pseudoaneurysms can also arise from the ICA along its cervical, petrous (Fig 3), or cavernous (Fig 4) segments. In the case of a traumatic cavernous ICA
pseudoaneurysm, epistaxis results from rupture into the sphenoid sinus to which the ICA is intimately related along its cavernous segment. The latent period, which is most likely due to progressive weakening of the arterial wall and erosion of adjacent bone, can vary from several days to many years, with most cases presenting within 3 weeks after trauma (88%). Bleeding is usually characterized by repeated episodes, which become more severe with time, though the first hemorrhage may be fatal in rare instances. Treatment will depend on the vessel involved. In the example shown in Fig 2, surgical ligation of the right AEA was performed because at the time, this was considered to be safer than catheterization and embolization via the OphA. When the pseudoaneurysm arises directly from the ICA and test occlusion of the ICA is tolerated, permanent occlusion of the ICA can be achieved with either detachable balloons or coils. Resorting to obliteration of the aneurysmal lumen with preservation of the parent vessel when test occlusion is not tolerated may be hazardous due to the fragile nature of the pseudoaneurysmal wall. Alternatively, endovascular covered stents have been tried for similar lesions but still have technical drawbacks when delivered intracranially.

**Postoperative Epistaxis**

Surgical trauma to vessels of the sinonasal region can lead to postoperative nasal bleeding. When epistaxis develops shortly after surgery, the causal relationship will be apparent. This is illustrated in Fig 5 by a case of epistaxis several hours after septorhinoplasty. However, delayed epistaxis may also occur, analogous to traumatic epistaxis. For this reason, immediate postoperative angiography has been recommended in cases in which packing was required for sudden arterial bleeding during trans-sphenoidal surgery. When this does not reveal any abnormalities (e.g., occlusion, stenosis, or a pseudoaneurysm), delayed epistaxis is unlikely to occur but cannot be entirely ruled out, because a pseudoaneurysm may still develop. Moreover, epistaxis may also occur after seemingly uneventful or even minimally invasive surgery.

**Nontraumatic ICA Aneurysm**

Epistaxis is a very uncommon manifestation of intracavernous ICA aneurysms. When it occurs, a history of head injury is obtainable in 90% of cases. In the remaining cases, the aneurysm is either idiopathic or mycotic. The diagnostic and treatment strategies in these cases will be similar to those in traumatic ICA aneurysms, as detailed above. In case of a mycotic aneurysm, adjuvant antibacterial or antifungal agents can be administered if an active infection is still suspected.

**Arteriovenous Malformation**

Hemorrhage from an arteriovenous malformation (AVM) can present as epistaxis when either the lesion itself or its venous drainage pattern involves the oronasal cavity. Figure 6 demonstrates an AVM of the nose and upper lip in a patient presenting with a history of recurrent epistaxis. Skull base AVMs can present in a similar fashion and can be very challenging to treat due to reduced accessibility. In rare instances, an intracranial AVM draining through pharyngeal veins can cause massive epistaxis when these arterialized veins rupture (Fig 7). The treatment paradigm in these cases will not differ from that of other AVMs and includes surgery, embolization, radiosurgery, or a combination of these.

**Dural Arteriovenous Fistula**

A dural arteriovenous fistula (DAVF) can be asymptomatic or present with a variety of symptoms, including hemorrhage. The aggressiveness of the symptoms were shown to be related to the venous drainage pattern. DAVFs without cortical venous reflux are considered relatively benign, whereas fistulas producing cortical venous reflux are considered aggressive because they show a high annual event rate. When a DAVF is located in the anterior fossa, which occurs in...
approximately 10% of cases, it is supplied by the ethmoidal branches of the ophthalmic artery from 1 or both sides and drains into the superior sagittal sinus via cortical veins. Such lesions always show an aggressive drainage pattern, exhibit a strong male predominance, and present most frequently in the sixth decade. In rare instances, these can present with epistaxis, presumably due to erosion of the floor of the anterior fossa by aneurysmal dilation of a draining vein. Endovascular embolization with n-butyl cyanoacrylate was shown to be a viable treatment option for these lesions, with a relatively high success rate (63.6%) and low complication rate, followed by open surgery in case of failure.

**Hereditary Hemorrhagic Telangiectasia**

Hereditary hemorrhagic telangiectasia (HHT), also known as Osler-Weber-Rendu disease, is a systemic autosomal dominant condition characterized by vascular abnormalities of the nose, skin, lung, gastrointestinal tract, and central nervous system. The prevalence of HHT ranges from 1 in 2351 to 1 in 39,216 in different populations. Epistaxis caused by spontaneous bleeding from telangiectases of the nasal mucosa is the most common manifestation in these patients (Fig 8). It may be so severe as to require multiple transfusions or so mild that HHT is never suspected. Recurrent epistaxis usually presents during the first 2 decades of life and becomes more severe with time in approximately 2 of 3 patients. Other manifestations that appear later in life include telangiectases of the skin and, less frequently, pulmonary AVMs; central nervous system AVMs (Fig 8); and gastrointestinal telangiectases, AVMs, or angiodysplasias.

The difficulty in treating recurrent epistaxis in patients with HHT is reflected by the multitude of reported treatment options, including chemical, electrical, or ultrasonic cauterization; local or systemic hormone therapy; topical application of fibrin glue; photoocoagulation; transarterial embolization; brachytherapy; septal dermoplasty; vessel ligation; bleomycin injections; and the use of nasal obturators. Because none of these provide a definite cure, treatment is aimed at reducing the number and severity of epistaxis episodes. Though transarterial embolization may achieve this goal, re-

---

**Fig 10.** Imaging of a 65-year-old man who presented with intractable epistaxis and whose history included right nephrectomy for renal cell carcinoma 5 years earlier. A, Axial CT scan at the level of the ethmoid sinuses shows a soft-tissue mass in the posterior ethmoidal air cells (arrows). B, Left external carotid arteriogram demonstrates the neovascularity (arrow) supplied by the terminal IMA.

**Fig 11.** Angiography in a 62-year-old man with right-sided epistaxis, demonstrating a meningo-ophthalmic artery (ie, the OphA arises from the MMA). Selective catheterization of the IMA distal to the origin of the MMA was necessary to perform embolization safely. A, Right internal carotid arteriogram demonstrates the absence of the OphA arising from the internal carotid system. B, Right external carotid arteriogram, early arterial phase, reveals the meningo-ophthalmic artery (arrow). C, The same image as in B, late arterial phase, confirms the choroidal blush (arrows) arising from the external carotid system.
currence rates, requiring re-embolization or surgery, are generally higher in patients with HHT than in patients without HHT. Therefore, permanent proximal occlusion with coils is not advised because this may preclude re-embolization when distal collaterals result in recurrent episodes. Because mucosal perfusion returns to normal within 2–8 days after embolization, elective embolization (ie, embolization at a time when the patient is not actively bleeding) will not yield long-term control.

Sinonasal Neoplasms

Although almost any tumor in the sinonasal region can present with epistaxis, juvenile nasopharyngeal angiofibromas most commonly cause epistaxis requiring embolization. Juvenile nasopharyngeal angiofibromas are benign tumors that occur almost exclusively in young men, with the peak incidence between 14 and 17 years of age. They are highly vascular lesions (Fig 9), spreading via foramina and fissures in the skull base region. The feeding vessels are primarily the IMA or APhA, though tumor spread may lead to the recruitment of a secondary blood supply. Embolization of the accessible feeding vessels can be performed to control epistaxis and to prevent excessive bleeding during surgical resection. Small particles (50–150 μm) are used to penetrate and occlude intratumoral vessels, by using selective catheter positioning to avoid damage to surrounding tissue.

The remaining list of tumor types that can cause intractable epistaxis is varied and includes hemangioma, hemangiopericytoma, acute myelogenous leukemia, pyogenic granuloma gravidarum, nasopharyngeal carcinoma, malignant fibrous histiocytoma, adenoid cystic carcinoma, and metastatic disease (Fig 10). Analogous to juvenile nasopharyngeal angiofibromas, epistaxis may initially be controlled with embolization, but depending on the nature of the tumor, some will eventually require surgery and/or external beam radiation. After such aggressive treatment, epistaxis can occur due to residual or recurrent tumor or due to surgical- and radiation-induced damage to blood vessels. Epistaxis in these cases can be life-threatening, prompting rapid angiography, with abnormal findings in most of these cases, which will guide therapeutic choices.

Fig 12. Angiography in a 72-year-old woman with intractable idiopathic epistaxis, who was referred to surgery because an ECA origin of the OphA rendered embolization unsafe. A, Left common carotid arteriogram demonstrates ICA occlusion (arrow). B, The same image as A shows no antegrade or retrograde opacification of the OphA. C, Selective left IMA injection, early arterial phase, demonstrates collaterals from the SPA to the OphA (arrow) via an ethmoidal branch (double arrow). D, The same image as in C but in the late arterial phase shows the OphA (arrow) and choroidal blush (arrowheads).
Treatment Results and Complications
The ability to halt bleeding with embolization therapy immediately following the procedure has been reported to be between 93% and 100%, and persistent in 0%–1%, and persistent in 1%–2%. One group clearly demonstrated that the success rate depended on the embolization protocol used. Another report demonstrated the influence of the underlying pathology on the short-term and long-term success rates, with long-term success naturally being lowest in patients with HHT, because these patients have ongoing systematic pathology resulting in new episodes. In general, the success rates mentioned above best represent the results in idiopathic posterior epistaxis, given the distribution of pathologies in the cited reports.

Complications of embolization can be categorized as being minor transient, major transient, or persistent. Minor transient adverse events include headache, facial pain, jaw pain, trismus, facial edema, facial numbness, mild cold hypersensitivity, paresthesias, mild palate ulceration, altered mental status, groin hematoma, groin pain, or fever. Major transient complications include skin slough, temporary facial nerve paralysis, temporary monocular visual field loss, and mucosal necrosis. Persistent complications include facial scarring following ischemia, monocular blindness, peripheral facial nerve paralysis, cerebral infarction, and ischemic sialadenitis requiring surgery. Larger series report minor transient complications in 25%–59%, major transient in 0%–1%, and persistent in ≤2% of cases. Delayed diagnosis of an intranasal neoplasm has also been mentioned as a potential pitfall of embolization.

In comparison, the failure rate of surgical ligation to treat intractable epistaxis has been reported to be between 4.3% and 33%, and the recurrence rate varies between 93% and 100%. With the advent of endoscopic surgery, complication rates of surgery have decreased, with only minor complications being reported, including pain, posterior rhinorrhea, numbness of the palate and nose, nasal crusting, intranasal adhesions, and septal perforation. Thus, success and complication rates are quite comparable between surgical ligation and embolization, except that more serious major complications are associated with embolization.

Again, this stresses the need to be aware of angiographic findings that represent a communication between the ECA and the ICA or the OphA. Such findings may represent normal anastomoses, anatomic variants (Fig 11), or acquired collateralizations (Fig 12). When these are encountered, one should consider alteration of the embolization technique accordingly or referral to surgery.

Conclusions
Transarterial embolization is an accepted treatment option for intractable epistaxis, when epistaxis is refractory to conservative or surgical management. It is, however, associated with a small risk of serious morbidity that occurs when embolic material inadvertently enters the ICA or OphA. Therefore, one should be aware of possible communications between these vessels and the ECA and perform diagnostic angiography before treatment. Such angiography may also reveal less common causes of epistaxis, which would likely have an impact on the treatment strategy.

References
22. Osborne AG. Diagnostic Cerebral Angiography. Philadelphia: Lippincott Williams & Wilkins; 1943
32. Christensen NP, Smith DS, Barnwell SL, et al. Arterial embolization in the
management of posterior epistaxis. Otolaryngol Head Neck Surg 2003; 133:748–53